1-7 of 7
John F. Gerecitano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Caitlin M. Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Jr, Matthew J. Matasar, John F. Gerecitano, Pamela Drullinsky, Audrey Hamilton, David Straus, Steven M. Horwitz, Anita Kumar, Craig H. Moskowitz, Alison Moskowitz, Andrew D. Zelenetz, Jurgen Rademaker, Gilles Salles, Venkatraman Seshan, Heiko Schöder, Anas Younes, Dana W.Y. Tsui, Connie Lee Batlevi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 45–56.
https://doi.org/10.1158/1078-0432.CCR-21-2183
Published: 05 January 2022
View article titled, Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Open the PDF for Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring in another window
Includes: Supplementary data
Journal Articles

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Michael Hallek, William Wierda, Andrew W. Roberts, Stephan Stilgenbauer, Jeffrey A. Jones, John F. Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E. Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F. Seymour
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (18): 4371–4379.
https://doi.org/10.1158/1078-0432.CCR-17-3761
Published: 14 September 2018
View article titled, Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Open the PDF for Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Jacob D. Soumerai, Andrew D. Zelenetz, Craig H. Moskowitz, M. Lia Palomba, Paul A. Hamlin, Jr, Ariela Noy, David J. Straus, Alison J. Moskowitz, Anas Younes, Matthew J. Matasar, Steven M. Horwitz, Carol S. Portlock, Jason A. Konner, Mrinal M. Gounder, David M. Hyman, Martin H. Voss, Matthew G. Fury, Devika Gajria, Richard D. Carvajal, Alan L. Ho, Jan H. Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F. Little, Christine Jarjies, Thu O. Dang, Fallon France, Nishant Mishra, John F. Gerecitano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4119–4126.
https://doi.org/10.1158/1078-0432.CCR-16-3068
Published: 01 August 2017
View article titled, The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Open the PDF for The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino, John A. Martignetti
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1552–1563.
https://doi.org/10.1158/1078-0432.CCR-16-1333
Published: 14 March 2017
View article titled, Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Open the PDF for Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Jason R. Dobson, Adam S. Crystal, Sudha Parasuraman, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5696–5705.
https://doi.org/10.1158/1078-0432.CCR-16-1248
Published: 30 November 2016
View article titled, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials

Alexia Iasonos, Mrinal Gounder, David R. Spriggs, John F. Gerecitano, David M. Hyman, Sarah Zohar, John O'Quigley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5179–5187.
https://doi.org/10.1158/1078-0432.CCR-12-0726
Published: 30 September 2012
View article titled, The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials
Open the PDF for The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Owen A. O'Connor, A. Keith Stewart, Marcy Vallone, Christopher J. Molineaux, Lori A. Kunkel, John F. Gerecitano, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7085–7091.
https://doi.org/10.1158/1078-0432.CCR-09-0822
Published: 11 November 2009
View article titled, A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Open the PDF for A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies in another window